Preliminary off-treatment responses following 48 weeks of vebicorvir, nucleos(t) ide reverse transcriptase inhibitor, and ab-729 combination in virologically suppressed patients with hepatitis b e antigen negative chronic hepatitis b: analysis from an open-label phase 2 study